Active Tuberculous Infection among Adult Sudanese Patients on Long Term Peritoneal Dialysis by Shigidi, M et al.
135
Arab Journal of Nephrology and Transplantation
Arab Journal of Nephrology and Transplantation. 2012 Sep;5(3):135-40
Original Article AJNT
Abstract
Introduction: The prevalence of tuberculosis in Sudan is 
209 cases per 100,000 populations. There are no reports 
available regarding the prevalence of tuberculosis among 
the end-stage kidney disease and dialysis populations.
Methods: We reviewed the medical records of all 
adults who were on peritoneal dialysis (PD) in the 
Sudan Peritoneal Dialysis Program, during the period 
from June 2005 to December 2011. Those diagnosed as 
having active tuberculous infections were retrospectively 
studied regarding their demography, clinical presentation 
and outcomes.
Results: Out of 350 patients  in our program, 19 were 
diagnosed as having active tuberculosis (5.4%). All 
patients were diagnosed during their first year on 
peritoneal dialysis, 74% were males; the mean age was 
37 ± 11 years, extrapulmonary tuberculosis was seen in 
16/19 (84%) patients and it was abdominal in nine of the 
16 (47%) patients. In addition to high clinical suspicion, 
the diagnosis of active tuberculosis was supported by 
tissue biopsy findings in 16%, positive polymerase 
chain reaction in 26%, exudative ascites with suggestive 
radiological features in 21%, strongly positive tuberculin 
test in 21% and a favourable response to empirical 
antituberculous therapy in 26% of patients. HIV test was 
negative in all 19 patients and only one patient tested 
positive for hepatitis B viral infection. Antituberculous 
drugs side effects were seen in 68% of patients. Forty 
seven percent of patients showed complete recovery and 
continued on peritoneal dialysis. Our case fatality was 
32%.
Conclusion: Abdominal tuberculosis is common among 
PD patients and its diagnosis should always be considered 
in suspected patients. 
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Outcome; Sudan
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Introduction
A high burden of tuberculosis had been reported in 
Sudan, with a prevalence of 209 cases per 100,000 
populations [1]. Several reports showed that dialysis 
patients are at increased risk of developing tuberculosis 
when compared to normal people, as uremic patients are 
immune-compromised, and are at an increased risk of 
reactivating silent tuberculous infections [2-5]. 
Among end-stage renal disease patients, extrapulmonary 
tuberculosis had been reported in as many as 60% to 80% 
of cases, either alone or in association with pulmonary 
disease. The diagnosis of active tuberculous infection 
among dialysis patients is often difficult to make because 
of the prevailing extrapulmonary involvement and the 
nonspecific presenting symptoms, often mimicking 
those of uremia [6-9]. Accordingly, empirical treatment 
is always considered whenever there is a strong clinical 
suspicion of active tuberculosis in these patients despite 
the increased risk of antituberculous drugs toxicities [10, 
11]. The reported mortality rates of active infections 
among dialysis populations range from 0 - 75% [12-15]. 
Few reports are available regarding the prevalence of 
tuberculosis among end-stage kidney disease patients on 
peritoneal dialysis (PD). We hereby present our experience 
regarding the prevalence, management and outcome of 
active tuberculosis among PD patients enrolled in the 
Sudan National Peritoneal Dialysis Program, over a 
period of about six years.
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Methods
We reviewed the medical records of all end-stage renal 
disease patients who were on PD at the Sudan National PD 
program during the period from June 2005 to December 
2011. Those diagnosed as having active tuberculous 
infections were retrospectively studied regarding their 
demographic data, primary kidney disease, co-morbid 
diseases, past history of tuberculosis, duration on 
PD, clinical presentation, site of active tuberculosis, 
diagnostic methods used, antituberculous treatments 
given, antituberculous drugs adverse reactions and the 
overall response to therapy. 
The diagnosis of tuberculosis was established by the 
presence of a strong clinical suspicion in addition to one 
or more of the following features [16-20]: 
Caseous necrosis or granulomata on tissue biopsy.• 
Positive result of polymerase chain reaction (PCR) • 
for Mycobacterium tuberculosis.
Isolation of acid fast bacilli on Ziehl–Neelsen (ZN) • 
stain or culture techniques.
A strongly positive tuberculin test with more than 15 • 
mm induration in a non-vaccinated patient.
Suggestive ascitic or pleural fluid analysis in the • 
presence of radiological features of tuberculosis.
A definitive response to empirical antituberculous • 
therapy. 
In our center, the recommended initial antituberculous 
treatment regimen for those with chronic kidney disease 
or on dialysis therapy include two months of isoniazid, 
rifampicin, pyrazinamide and ethambutol, followed by 
four months of isoniazid and rifampicin; with appropriate 
dose adjustments for ethambutol and pyrazinamide [21, 
22]. A six months treatment course is usually considered 
sufficient in uncomplicated cases of active tuberculosis 
[23]. An extended course of up to 12 months is always 
recommended in those with tuberculosis of the bones, 
joints as well as tuberculous meningitis [24]. In those with 
tuberculous meningitis, oral ethambutol is replaced by 
injectable streptomycin [25]. Among multidrug resistant 
patients, retreatment regimen is augmented by use of 
second line drugs such as fluoroquinolone or injectable 
streptomycin, till drug sensitivity data is available. 
Data were extracted from the various PD Units’ 
medical records and entered into a specially designed 
questionnaire. We analyzed the concomitant risk factors 
for developing tuberculosis, clinical presentations 
and laboratory findings, treatment regimens given, 
response of therapy, drugs adverse effects, compliance 
and outcomes. Therapeutics methods and outcomes 
were reviewed and analyzed. Results were expressed as 
means and standard deviations for continuous data, and 
frequencies and percentages for categorical data.
Results
During the period from June 2005 to December 2011, 
350 adult patients were on PD (231 male, 119 female), of 
these 19 patients were diagnosed and treated as having 
active tuberculous infection, making a prevalence rate of 
tuberculosis of 5.4% in our program. Those 19 patients 
with active tuberculosis were included in the study. They 
were all on continuous ambulatory peritoneal dialysis; 
their mean age was 37 ± 11 years (range 18 - 60 years). 
Males were predominantly affected, 14 out of 19 patients 
(74%). All patients were diagnosed as having tuberculosis 
during their first year on PD. Primary glomerulonephritis 
was the native kidney disease in eight patients (42%), 
followed by obstructive uropathy in four patients (21%). 
Three patients (16%) gave a past medical history of 
tuberculosis for which they received previous full courses 
of antituberculous therapy; two patients (10%) were 
diabetics, whereas three patients (16%) were on long 
term steroids for their primary kidney diseases before 
reaching end-stage renal disease. Patients’ characteristics 
are shown in Table-1. 
Extra-pulmonary tuberculosis was seen in 16 patients 
(84%), of these nine (47%) presented with abdominal 
tuberculosis. Isolated pulmonary tuberculosis was seen 
in three out of 19 patients (16%). The most common 
presenting symptoms were fatigue, fever and marked 
weight loss was seen in 84%, 63% and 47% of patients, 
respectively (Table-2). In addition to high clinical 
suspicion, the diagnosis of tuberculosis was supported by 
histological evidence of tuberculosis on tissue biopsy in 
three patients (16%), positive PCR in five patients (26%) 
and strongly positive tuberculin tests of more than 15 
mm induration in four patients (21%). In four patients 
(21%) the diagnosis of abdominal tuberculosis was 
supported by the presence of exudative ascites together 
with suggestive radiological features on computed 
tomographic scanning. An overlap of these diagnostic 
findings was seen in few patients; whereas empirical 
antituberculous therapy was given in five patients (26%). 
Acid fast bacilli were not isolated in any of our patients 
including those with pulmonary tuberculosis. Assessment 
for HIV was done for all patients and was negative. 
Hepatitis B viral infection was found in one patient. The 
mean serum albumin level was 3.3 ± 0.5 g/dl.
Sixteen patients were treated with isoniazid, rifampicin, 
pyrazinamide and ethambutol for 6-12 months. 
Three patients were treated with second line protocol 
regimen due to history of tuberculosis  previously 
treated with full  antituberculous therapy. All patients 
received oral pyridoxine as part of the antituberculous 
protocol. Drug compliance was ensured in all patients 
by the close follow-up of enthusiastic PD nursing staff. 
Antituberculous drugs adverse effects were seen in 
68% of patients (Table-3). Adverse effects were severe 
enough to alter therapy in four out of 19 patients (21%); 
those side effects were optic neuritis (three patients) and 
hepatic encephalopathy (one patient). 
Out of a total of 19 patients, nine patients (47%) showed 
complete recovery and continued on PD, four patients 
(21%) were shifted to hemodialysis and six patients (32%) 
died. Among those shifted to HD, three had abdominal 
Characteristics Number of Patients (%)
Total 19 / 350 (5.4%)
Mean age in years 37 ± 11
Sex (male / female) 14 (74%) / 5 (26%)
Past history of tuberculosis  3 (16%)
Primary kidney disease
  Glomerulonephritis 8 (42%)
  Obstructive uropathy 4 (21%)
  Diabetic nephropathy 2 (11%)
  Hypertensive nephrosclerosis 1 (5%)
  Lupus nephritis 1 (5%)
  Unknown 3 (16%)
Site of tuberculosis
  Abdomen 9 (47%)
  Pulmonary 3 (16%)
  Lymph nodes 3 (16%)
  Disseminated* 3 (16%)
  Joint 1 (5%)
Outcome
  Improved and on peritoneal dialysis 9 (47%)
  Shifted to hemodialysis 4 (21%)
  Died 6 (32%)
Table 1: Characteristics of PD patients with active 
tuberculosis
* Multiple sites with tuberculous involvement
Clinical manifestation Frequency (%)
Fatigability 16 (84%)
Fever 12 (63%)
Marked weight loss 9 (47%)
Abdominal Pain 6 (32%)
Turbid PD effluent 6 (32%)
Cough 4 (21%)
Multiple lymph node enlargements 3 (16%)
Painful swollen joint 1 (5%)
Table 2: Clinical manifestations among PD patients with 
active tuberculosis
Overlap of symptoms was seen in more than one patient
Table 3: Occurrence of antituberculous drugs adverse 
reactions
Adverse Reactions Frequency (%)
Gastrointestinal symptoms 4 (31%)
Psychiatric manifestations 3 (23%)
Optic neuritis 3 (23%)
Peripheral neuropathy 2 (15%)
Hepatotoxicity 1 (8%)
Table 4: Characteristic features of mortality patients
Sex Age Kidney isease Co-morbid Conditions Site of Tuerculosis Diagnostic Test Cause of Death




history of treated TB
Disseminated TB PCR Hepatic failure
M 18 GN Long course of steroids Disseminated TB PCR Brain tuberculoma
M 45 Unknown Cardiomyopathy Disseminated TB PCR Sepsis, coma
M 50 HTN Malnutrition TB Lymphadenitis Tissue biopsy Peritonitis, sepsis
M 24 GN - TB Lymphadenitis Tissue biopsy Unknown
M 42 Obstructive 
uropathy




TB: tuberculosis; PCR: polymerase chain reaction for tuberculosis; GN: glomerulonephritis; HTN: hypertension; CT: computed tomographic scan; 
tuberculin test: strongly positive tuberculin test
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Methods
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disease patients who were on PD at the Sudan National PD 
program during the period from June 2005 to December 
2011. Those diagnosed as having active tuberculous 
infections were retrospectively studied regarding their 
demographic data, primary kidney disease, co-morbid 
diseases, past history of tuberculosis, duration on 
PD, clinical presentation, site of active tuberculosis, 
diagnostic methods used, antituberculous treatments 
given, antituberculous drugs adverse reactions and the 
overall response to therapy. 
The diagnosis of tuberculosis was established by the 
presence of a strong clinical suspicion in addition to one 
or more of the following features [16-20]: 
Caseous necrosis or granulomata on tissue biopsy.• 
Positive result of polymerase chain reaction (PCR) • 
for Mycobacterium tuberculosis.
Isolation of acid fast bacilli on Ziehl–Neelsen (ZN) • 
stain or culture techniques.
A strongly positive tuberculin test with more than 15 • 
mm induration in a non-vaccinated patient.
Suggestive ascitic or pleural fluid analysis in the • 
presence of radiological features of tuberculosis.
A definitive response to empirical antituberculous • 
therapy. 
In our center, the recommended initial antituberculous 
treatment regimen for those with chronic kidney disease 
or on dialysis therapy include two months of isoniazid, 
rifampicin, pyrazinamide and ethambutol, followed by 
four months of isoniazid and rifampicin; with appropriate 
dose adjustments for ethambutol and pyrazinamide [21, 
22]. A six months treatment course is usually considered 
sufficient in uncomplicated cases of active tuberculosis 
[23]. An extended course of up to 12 months is always 
recommended in those with tuberculosis of the bones, 
joints as well as tuberculous meningitis [24]. In those with 
tuberculous meningitis, oral ethambutol is replaced by 
injectable streptomycin [25]. Among multidrug resistant 
patients, retreatment regimen is augmented by use of 
second line drugs such as fluoroquinolone or injectable 
streptomycin, till drug sensitivity data is available. 
Data were extracted from the various PD Units’ 
medical records and entered into a specially designed 
questionnaire. We analyzed the concomitant risk factors 
for developing tuberculosis, clinical presentations 
and laboratory findings, treatment regimens given, 
response of therapy, drugs adverse effects, compliance 
and outcomes. Therapeutics methods and outcomes 
were reviewed and analyzed. Results were expressed as 
means and standard deviations for continuous data, and 
frequencies and percentages for categorical data.
Results
During the period from June 2005 to December 2011, 
350 adult patients were on PD (231 male, 119 female), of 
these 19 patients were diagnosed and treated as having 
active tuberculous infection, making a prevalence rate of 
tuberculosis of 5.4% in our program. Those 19 patients 
with active tuberculosis were included in the study. They 
were all on continuous ambulatory peritoneal dialysis; 
their mean age was 37 ± 11 years (range 18 - 60 years). 
Males were predominantly affected, 14 out of 19 patients 
(74%). All patients were diagnosed as having tuberculosis 
during their first year on PD. Primary glomerulonephritis 
was the native kidney disease in eight patients (42%), 
followed by obstructive uropathy in four patients (21%). 
Three patients (16%) gave a past medical history of 
tuberculosis for which they received previous full courses 
of antituberculous therapy; two patients (10%) were 
diabetics, whereas three patients (16%) were on long 
term steroids for their primary kidney diseases before 
reaching end-stage renal disease. Patients’ characteristics 
are shown in Table-1. 
Extra-pulmonary tuberculosis was seen in 16 patients 
(84%), of these nine (47%) presented with abdominal 
tuberculosis. Isolated pulmonary tuberculosis was seen 
in three out of 19 patients (16%). The most common 
presenting symptoms were fatigue, fever and marked 
weight loss was seen in 84%, 63% and 47% of patients, 
respectively (Table-2). In addition to high clinical 
suspicion, the diagnosis of tuberculosis was supported by 
histological evidence of tuberculosis on tissue biopsy in 
three patients (16%), positive PCR in five patients (26%) 
and strongly positive tuberculin tests of more than 15 
mm induration in four patients (21%). In four patients 
(21%) the diagnosis of abdominal tuberculosis was 
supported by the presence of exudative ascites together 
with suggestive radiological features on computed 
tomographic scanning. An overlap of these diagnostic 
findings was seen in few patients; whereas empirical 
antituberculous therapy was given in five patients (26%). 
Acid fast bacilli were not isolated in any of our patients 
including those with pulmonary tuberculosis. Assessment 
for HIV was done for all patients and was negative. 
Hepatitis B viral infection was found in one patient. The 
mean serum albumin level was 3.3 ± 0.5 g/dl.
Sixteen patients were treated with isoniazid, rifampicin, 
pyrazinamide and ethambutol for 6-12 months. 
Three patients were treated with second line protocol 
regimen due to history of tuberculosis  previously 
treated with full  antituberculous therapy. All patients 
received oral pyridoxine as part of the antituberculous 
protocol. Drug compliance was ensured in all patients 
by the close follow-up of enthusiastic PD nursing staff. 
Antituberculous drugs adverse effects were seen in 
68% of patients (Table-3). Adverse effects were severe 
enough to alter therapy in four out of 19 patients (21%); 
those side effects were optic neuritis (three patients) and 
hepatic encephalopathy (one patient). 
Out of a total of 19 patients, nine patients (47%) showed 
complete recovery and continued on PD, four patients 
(21%) were shifted to hemodialysis and six patients (32%) 
died. Among those shifted to HD, three had abdominal 
Characteristics Number of Patients (%)
Total 19 / 350 (5.4%)
Mean age in years 37 ± 11
Sex (male / female) 14 (74%) / 5 (26%)
Past history of tuberculosis  3 (16%)
Primary kidney disease
  Glomerulonephritis 8 (42%)
  Obstructive uropathy 4 (21%)
  Diabetic nephropathy 2 (11%)
  Hypertensive nephrosclerosis 1 (5%)
  Lupus nephritis 1 (5%)
  Unknown 3 (16%)
Site of tuberculosis
  Abdomen 9 (47%)
  Pulmonary 3 (16%)
  Lymph nodes 3 (16%)
  Disseminated* 3 (16%)
  Joint 1 (5%)
Outcome
  Improved and on peritoneal dialysis 9 (47%)
  Shifted to hemodialysis 4 (21%)
  Died 6 (32%)
Table 1: Characteristics of PD patients with active 
tuberculosis
* Multiple sites with tuberculous involvement
Clinical manifestation Frequency (%)
Fatigability 16 (84%)
Fever 12 (63%)
Marked weight loss 9 (47%)
Abdominal Pain 6 (32%)
Turbid PD effluent 6 (32%)
Cough 4 (21%)
Multiple lymph node enlargements 3 (16%)
Painful swollen joint 1 (5%)
Table 2: Clinical manifestations among PD patients with 
active tuberculosis
Overlap of symptoms was seen in more than one patient
Table 3: Occurrence of antituberculous drugs adverse 
reactions
Adverse Reactions Frequency (%)
Gastrointestinal symptoms 4 (31%)
Psychiatric manifestations 3 (23%)
Optic neuritis 3 (23%)
Peripheral neuropathy 2 (15%)
Hepatotoxicity 1 (8%)
Table 4: Characteristic features of mortality patients
Sex Age Kidney isease Co-morbid Conditions Site of Tuerculosis Diagnostic Test Cause of Death




history of treated TB
Disseminated TB PCR Hepatic failure
M 18 GN Long course of steroids Disseminated TB PCR Brain tuberculoma
M 45 Unknown Cardiomyopathy Disseminated TB PCR Sepsis, coma
M 50 HTN Malnutrition TB Lymphadenitis Tissue biopsy Peritonitis, sepsis
M 24 GN - TB Lymphadenitis Tissue biopsy Unknown
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TB: tuberculosis; PCR: polymerase chain reaction for tuberculosis; GN: glomerulonephritis; HTN: hypertension; CT: computed tomographic scan; 
tuberculin test: strongly positive tuberculin test
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tuberculosis, while the fourth patient had tuberculous 
lymphadenitis. Reasons for switching to hemodialysis 
were abdominal adhesions in one patient, PD catheter tip 
migration in one patient and recurrent bacterial peritonitis 
in two patients.  The characteristic features of those who 
died are shown in Table-4. 
Discussion
Sudan was reported as a country with high prevalence 
of tuberculosis. In this study we reviewed the records 
of all adult patients with active tuberculosis who were 
on PD. Similar to previously published reports, active 
tuberculosis among our patients was mostly diagnosed 
during the first year on PD, with a relatively high 
prevalence of extra-pulmonary disease, 84% [12, 13], a 
fact that had been attributed to the poor general health 
at the start of dialysis, a time at which patients’ cellular 
immunity is mostly depressed [5]. The commonest 
extrapulmonary site affected was the abdomen.  This is 
in agreement with work of Sanai and Bzeizi  who noted 
that abdominal tuberculosis included involvement of the 
gastrointestinal tract, peritoneum or the mesenteric lymph 
nodes, with occasional overlaps of these forms [23]. 
Isolation of the mycobacteria by culture techniques 
remains the gold standard for the diagnosis of  tuberculosis 
[26]. Culture techniques for the isolation of acid- fast 
bacilli and laproscopic peritoneal biopsy are not readily 
available at our centers. Ziehl–Neelsen staining of 
sputum and/or ascitic fluid for mycobacteria, though 
performed in all suspected patients, was confronted by a 
poor detection yield at our centers.  It had been reported 
that for the detection of mycobacteria in stained smears, 
a presence of at least 5000 bacilli/ml of specimen is 
required [27, 28]; usually, only about 3% of proven 
tuberculous peritonitis patients are expected to show 
positive tests on ascitic fluid ZN staining [23]. Failure 
of isolation of mycobacteria via ZN staining of sputum 
and/or ascitic fluid among our patients denotes the poor 
sensitivity of this technique [17].
Detection of mycobacteria by gene amplification and 
PCR is known to have a high sensitivity of up to 95% in 
smear positive patients. The PCR detection yield in smear 
negative patients is also known to be disappointingly low, 
reaching 48% [29]. Detection of mycobacteria via PCR 
was available only of late at our program and the test was 
applied for 12 out of 19 PD patients, it showed a positive 
detection yield of 42%.  
The tuberculin test is greatly relied on in our country 
for screening and diagnostic support. Among dialysis 
patients, the presence of a negative tuberculin test is 
the usual rule due to the altered immunity, thus greatly 
reducing the sensitivity of the test. However the high 
specifity of this test (ranging between 95 – 99%) is not 
altered among dialysis patients, making the presence 
of a strongly positive  tuberculin test in suspected 
unvaccinated patients of great diagnostic value [30, 31]. 
In endemic areas the diagnosis of tuberculosis should 
always be considered in suspected patients. It is believed 
that favorable outcomes are greatly attributed to the early 
diagnosis and initiation of therapy [32, 33]. Removal of 
PD catheters was not essential to attain cure among patients 
with abdominal tuberculosis. Despite antituberculous 
therapy our mortality was high reaching 32%, raising the 
issue of screening for latent tuberculosis among dialysis 
patients in endemic areas like Sudan [34].
Conclusion
In conclusion, the diagnosis of active tuberculosis among 
PD patients requires a high index of clinical suspicion 
[35]. Abdominal tuberculosis remains to be common 
among PD patients and its diagnosis should always be 
considered in those with culture negative peritonitis. The 
high incidence of antituberculous drugs adverse effects 
warrants additional close monitoring in this group. Early 
initiation of dialysis and improvement of nutritional 
support among end-stage kidney disease patients might 
reduce the high risk of tuberculosis among dialysis 
patients [36]. 
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tuberculosis, while the fourth patient had tuberculous 
lymphadenitis. Reasons for switching to hemodialysis 
were abdominal adhesions in one patient, PD catheter tip 
migration in one patient and recurrent bacterial peritonitis 
in two patients.  The characteristic features of those who 
died are shown in Table-4. 
Discussion
Sudan was reported as a country with high prevalence 
of tuberculosis. In this study we reviewed the records 
of all adult patients with active tuberculosis who were 
on PD. Similar to previously published reports, active 
tuberculosis among our patients was mostly diagnosed 
during the first year on PD, with a relatively high 
prevalence of extra-pulmonary disease, 84% [12, 13], a 
fact that had been attributed to the poor general health 
at the start of dialysis, a time at which patients’ cellular 
immunity is mostly depressed [5]. The commonest 
extrapulmonary site affected was the abdomen.  This is 
in agreement with work of Sanai and Bzeizi  who noted 
that abdominal tuberculosis included involvement of the 
gastrointestinal tract, peritoneum or the mesenteric lymph 
nodes, with occasional overlaps of these forms [23]. 
Isolation of the mycobacteria by culture techniques 
remains the gold standard for the diagnosis of  tuberculosis 
[26]. Culture techniques for the isolation of acid- fast 
bacilli and laproscopic peritoneal biopsy are not readily 
available at our centers. Ziehl–Neelsen staining of 
sputum and/or ascitic fluid for mycobacteria, though 
performed in all suspected patients, was confronted by a 
poor detection yield at our centers.  It had been reported 
that for the detection of mycobacteria in stained smears, 
a presence of at least 5000 bacilli/ml of specimen is 
required [27, 28]; usually, only about 3% of proven 
tuberculous peritonitis patients are expected to show 
positive tests on ascitic fluid ZN staining [23]. Failure 
of isolation of mycobacteria via ZN staining of sputum 
and/or ascitic fluid among our patients denotes the poor 
sensitivity of this technique [17].
Detection of mycobacteria by gene amplification and 
PCR is known to have a high sensitivity of up to 95% in 
smear positive patients. The PCR detection yield in smear 
negative patients is also known to be disappointingly low, 
reaching 48% [29]. Detection of mycobacteria via PCR 
was available only of late at our program and the test was 
applied for 12 out of 19 PD patients, it showed a positive 
detection yield of 42%.  
The tuberculin test is greatly relied on in our country 
for screening and diagnostic support. Among dialysis 
patients, the presence of a negative tuberculin test is 
the usual rule due to the altered immunity, thus greatly 
reducing the sensitivity of the test. However the high 
specifity of this test (ranging between 95 – 99%) is not 
altered among dialysis patients, making the presence 
of a strongly positive  tuberculin test in suspected 
unvaccinated patients of great diagnostic value [30, 31]. 
In endemic areas the diagnosis of tuberculosis should 
always be considered in suspected patients. It is believed 
that favorable outcomes are greatly attributed to the early 
diagnosis and initiation of therapy [32, 33]. Removal of 
PD catheters was not essential to attain cure among patients 
with abdominal tuberculosis. Despite antituberculous 
therapy our mortality was high reaching 32%, raising the 
issue of screening for latent tuberculosis among dialysis 
patients in endemic areas like Sudan [34].
Conclusion
In conclusion, the diagnosis of active tuberculosis among 
PD patients requires a high index of clinical suspicion 
[35]. Abdominal tuberculosis remains to be common 
among PD patients and its diagnosis should always be 
considered in those with culture negative peritonitis. The 
high incidence of antituberculous drugs adverse effects 
warrants additional close monitoring in this group. Early 
initiation of dialysis and improvement of nutritional 
support among end-stage kidney disease patients might 
reduce the high risk of tuberculosis among dialysis 
patients [36]. 
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